- Email: [email protected]
North America special issue Part II
Journal of Controlled Release 240 (2016) 1
Contents lists available at ScienceDirect
Journal of Controlled Release journal homepage: www.elsevier.com/locate/jconrel
Editorial
North America special issue Part II
We are pleased to introduce Part II of the two-part North America special issue of the Journal of Controlled Release. In total, the two-part special issue contains nearly 100 reviews from drug delivery experts in North America. We kick off Part II with a piece from Editor-in-chief of the Journal of Controlled Release, Kinam Park, that describes the drop in productivity in the drug delivery field, as measured by the number of clinically used formulations, during the period of 1980-2010 as compared to 1950-1980. Park highlights the difficulties in translating second generation drug delivery systems into useful products, which he asserts is largely due to poor understanding of biological and immunological barriers. He calls for questioning of the status quo to re-accelerate the evolutionary process in the drug delivery field. The article sets the stage for the rest of Part II, which contains perspectives and insights from an additional 41 drug delivery experts in North America who are striving to reignite the fire of impactful innovation. Topics include approaches for overcoming barriers to regional delivery (e.g. central nervous system, gastroin-
http://dx.doi.org/10.1016/j.jconrel.2016.09.027 0168-3659/© 2016 Published by Elsevier B.V.
testinal tract, respiratory tract, tumors, vasculature), overcoming barriers to intracellular delivery, and overcoming limitations in delivery of intact and functional complex molecules, biologics, and cells. Further, approaches for modifying the immune system (e.g. vaccines, immunomodulation) and overcoming the immune system as a barrier (e.g. extending circulation time) are discussed. The range of topics in Part II addresses many of the important challenges that limit the effective translation of drug delivery technologies into products that improve the lives of patients. We hope that readers, young and “seasoned” alike, will be as inspired as we are by this unique two-part North America special issue.
Justin Hanes Laura M. Ensign Rangaramanujam Kannan Jung Soo Suk
Contents lists available at ScienceDirect
Journal of Controlled Release journal homepage: www.elsevier.com/locate/jconrel
Editorial
North America special issue Part II
We are pleased to introduce Part II of the two-part North America special issue of the Journal of Controlled Release. In total, the two-part special issue contains nearly 100 reviews from drug delivery experts in North America. We kick off Part II with a piece from Editor-in-chief of the Journal of Controlled Release, Kinam Park, that describes the drop in productivity in the drug delivery field, as measured by the number of clinically used formulations, during the period of 1980-2010 as compared to 1950-1980. Park highlights the difficulties in translating second generation drug delivery systems into useful products, which he asserts is largely due to poor understanding of biological and immunological barriers. He calls for questioning of the status quo to re-accelerate the evolutionary process in the drug delivery field. The article sets the stage for the rest of Part II, which contains perspectives and insights from an additional 41 drug delivery experts in North America who are striving to reignite the fire of impactful innovation. Topics include approaches for overcoming barriers to regional delivery (e.g. central nervous system, gastroin-
http://dx.doi.org/10.1016/j.jconrel.2016.09.027 0168-3659/© 2016 Published by Elsevier B.V.
testinal tract, respiratory tract, tumors, vasculature), overcoming barriers to intracellular delivery, and overcoming limitations in delivery of intact and functional complex molecules, biologics, and cells. Further, approaches for modifying the immune system (e.g. vaccines, immunomodulation) and overcoming the immune system as a barrier (e.g. extending circulation time) are discussed. The range of topics in Part II addresses many of the important challenges that limit the effective translation of drug delivery technologies into products that improve the lives of patients. We hope that readers, young and “seasoned” alike, will be as inspired as we are by this unique two-part North America special issue.
Justin Hanes Laura M. Ensign Rangaramanujam Kannan Jung Soo Suk